Wall Street brokerages expect that Accelerate Diagnostics Inc (NASDAQ:AXDX) will post $5.08 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Accelerate Diagnostics’ earnings, with the lowest sales estimate coming in at $3.72 million and the highest estimate coming in at $5.82 million. Accelerate Diagnostics posted sales of $1.80 million in the same quarter last year, which would indicate a positive year over year growth rate of 182.2%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 18th.

According to Zacks, analysts expect that Accelerate Diagnostics will report full year sales of $10.90 million for the current year, with estimates ranging from $9.54 million to $11.65 million. For the next year, analysts expect that the firm will post sales of $28.43 million, with estimates ranging from $24.79 million to $35.01 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Accelerate Diagnostics.

Accelerate Diagnostics (NASDAQ:AXDX) last released its earnings results on Thursday, November 7th. The medical research company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.01. Accelerate Diagnostics had a negative return on equity of 249.46% and a negative net margin of 1,116.69%. The firm had revenue of $2.27 million during the quarter, compared to analysts’ expectations of $3.15 million.

Several equities analysts have recently issued reports on the company. ValuEngine raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. lowered shares of Accelerate Diagnostics from a “neutral” rating to an “underweight” rating and set a $16.00 target price on the stock. in a research note on Friday, September 27th. BidaskClub cut shares of Accelerate Diagnostics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 2nd. Finally, Piper Jaffray Companies decreased their price target on shares of Accelerate Diagnostics from $22.00 to $19.00 and set a “positive” rating for the company in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $18.67.

Several hedge funds have recently modified their holdings of the stock. AXA boosted its stake in shares of Accelerate Diagnostics by 304.0% during the second quarter. AXA now owns 1,762,505 shares of the medical research company’s stock worth $40,326,000 after buying an additional 1,326,233 shares during the period. C WorldWide Group Holding A S lifted its stake in Accelerate Diagnostics by 357.5% during the second quarter. C WorldWide Group Holding A S now owns 524,683 shares of the medical research company’s stock worth $12,005,000 after purchasing an additional 410,000 shares during the period. Chicago Capital LLC boosted its holdings in Accelerate Diagnostics by 61.3% during the third quarter. Chicago Capital LLC now owns 881,390 shares of the medical research company’s stock valued at $16,367,000 after purchasing an additional 335,111 shares in the last quarter. BlackRock Inc. grew its stake in shares of Accelerate Diagnostics by 15.4% in the 2nd quarter. BlackRock Inc. now owns 2,004,650 shares of the medical research company’s stock valued at $45,865,000 after purchasing an additional 267,704 shares during the period. Finally, Griffin Asset Management Inc. grew its stake in shares of Accelerate Diagnostics by 48.1% in the 3rd quarter. Griffin Asset Management Inc. now owns 814,749 shares of the medical research company’s stock valued at $15,130,000 after purchasing an additional 264,703 shares during the period. Hedge funds and other institutional investors own 53.85% of the company’s stock.

AXDX stock traded up $0.03 during mid-day trading on Thursday, reaching $14.63. The company had a trading volume of 120,700 shares, compared to its average volume of 242,438. The company has a debt-to-equity ratio of 12.81, a quick ratio of 20.65 and a current ratio of 21.93. The company has a market capitalization of $799.53 million, a price-to-earnings ratio of -9.03 and a beta of 2.71. The firm has a fifty day simple moving average of $16.34 and a 200 day simple moving average of $18.64. Accelerate Diagnostics has a fifty-two week low of $10.23 and a fifty-two week high of $24.00.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Further Reading: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.